JP2024509576A5 - - Google Patents
Info
- Publication number
- JP2024509576A5 JP2024509576A5 JP2023555157A JP2023555157A JP2024509576A5 JP 2024509576 A5 JP2024509576 A5 JP 2024509576A5 JP 2023555157 A JP2023555157 A JP 2023555157A JP 2023555157 A JP2023555157 A JP 2023555157A JP 2024509576 A5 JP2024509576 A5 JP 2024509576A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- signature
- hla
- tme
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158825P | 2021-03-09 | 2021-03-09 | |
| US63/158,825 | 2021-03-09 | ||
| PCT/US2022/019633 WO2022192457A1 (en) | 2021-03-09 | 2022-03-09 | Predicting response to treatments in patients with clear cell renal cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509576A JP2024509576A (ja) | 2024-03-04 |
| JP2024509576A5 true JP2024509576A5 (https=) | 2025-03-05 |
Family
ID=80999772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555157A Pending JP2024509576A (ja) | 2021-03-09 | 2022-03-09 | 明細胞腎細胞がんを有する患者における治療に対する応答の予測 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220319638A1 (https=) |
| EP (1) | EP4305211A1 (https=) |
| JP (1) | JP2024509576A (https=) |
| CA (1) | CA3212968A1 (https=) |
| WO (1) | WO2022192457A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114565761B (zh) * | 2022-02-25 | 2023-01-17 | 无锡市第二人民医院 | 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法 |
| CN116121376A (zh) * | 2022-10-18 | 2023-05-16 | 中国人民解放军总医院第三医学中心 | Nmrk2作为诊断基因易位性肾细胞癌标记物的应用 |
| WO2024091607A1 (en) * | 2022-10-27 | 2024-05-02 | The Regents Of The University Of Michigan | Compositions and methods for treating renal cancer |
| US20240177803A1 (en) | 2022-11-17 | 2024-05-30 | Bostongene Corporation | Comprehensive immunoprofiling of peripheral blood |
| EP4695425A1 (en) * | 2023-04-13 | 2026-02-18 | BostonGene Corporation | Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| CN117987552A (zh) * | 2024-01-30 | 2024-05-07 | 四川大学华西医院 | 延胡索酸水合酶缺陷型肾细胞癌诊断标志物 |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| CN119162113A (zh) * | 2024-08-29 | 2024-12-20 | 河北省科学院生物研究所 | 一种杂交瘤细胞株及其产生的抗狐狸骨骼肌肌钙蛋白单克隆抗体和抗体的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| GB202209539D0 (en) | 2017-06-13 | 2022-08-10 | Bostongene Corp | Systems and methods for identifying cancer treatments from normalized biomarker scores |
-
2022
- 2022-03-09 WO PCT/US2022/019633 patent/WO2022192457A1/en not_active Ceased
- 2022-03-09 US US17/691,041 patent/US20220319638A1/en active Pending
- 2022-03-09 CA CA3212968A patent/CA3212968A1/en active Pending
- 2022-03-09 JP JP2023555157A patent/JP2024509576A/ja active Pending
- 2022-03-09 EP EP22714047.2A patent/EP4305211A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024509576A5 (https=) | ||
| Saichi et al. | Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity | |
| Zhang et al. | Identification of a novel ECM remodeling macrophage subset in AKI to CKD transition by integrative spatial and single‐cell analysis | |
| Mijnheer et al. | Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation | |
| US20240282449A1 (en) | Methods and systems for machine learning analysis of inflammatory skin diseases | |
| Su et al. | Multimodal single‐cell analyses outline the immune microenvironment and therapeutic effectors of interstitial cystitis/bladder pain syndrome | |
| US20220319638A1 (en) | Predicting response to treatments in patients with clear cell renal cell carcinoma | |
| JP2021072778A5 (https=) | ||
| US20240219385A1 (en) | Molecular signatures of long-term covid-19 and treatment thereof | |
| WO2014107533A2 (en) | Characterizing a glatiramer acetate related drug product | |
| US20230340601A1 (en) | Transcriptome Analysis For Treating Inflammation | |
| US20240167933A1 (en) | Flow cytometry immunoprofiling of peripheral blood | |
| US20240094217A1 (en) | Methods of treating sars-cov-2 infections | |
| US20250391505A1 (en) | Methods and Systems for Machine Learning Analysis of Lupus Nephritis | |
| De Groot et al. | Biological and clinical implications of gene-expression profiling in diffuse large B-cell lymphoma: a proposal for a targeted BLYM-777 consortium panel as part of a multilayered analytical approach | |
| Wang et al. | Single-cell transcriptomics of blood identified IFIT1+ neutrophil subcluster expansion in NTM-PD patients | |
| JP2024541909A5 (https=) | ||
| Ding et al. | A distinct immune landscape in anti-synthetase syndrome profiled by a single-cell genomic study | |
| US20240150453A1 (en) | Methods of predicting response to anti-tnf blockade in inflammatory bowel disease | |
| JP2024509273A5 (https=) | ||
| Ning et al. | Key pathways involved in prostate cancer based on gene set enrichment analysis and meta analysis | |
| JP2024512426A5 (https=) | ||
| US20260117297A1 (en) | Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases | |
| Xin et al. | Lignature: A Comprehensive Database of Ligand Signatures to Predict Cell-Cell Communication | |
| Tariq et al. | Type-1 interferon-driven innate and GZMK+ CD8 T cell activation precedes subclinical joint inflammation when rheumatoid arthritis is imminent |